期刊
DIGESTIVE AND LIVER DISEASE
卷 47, 期 2, 页码 119-124出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.dld.2014.11.007
关键词
Abdominal pain; Irritable bowel syndrome; Probiotic; Saccharomyces cerevisiae; Yeast
资金
- Lesaffre International
- Lesaffre
Background: We aimed to evaluate clinical symptoms in subjects with irritable bowel syndrome receiving Saccharomyces cerevisiae in a randomized double-blind placebo-controlled clinical trial. Methods: Overall, 179 adults with irritable bowel syndrome (Rome III criteria) were randomized to receive once daily 500 mg of Saccharomyces cerevisiae, delivered by one capsule (n=86, F: 84%, age: 42.5 +/- 12.5), or placebo (n=93, F: 88%, age: 45.4 +/- 14) for 8 weeks followed by a 3-week washout period. After a 2-week run-in period, cardinal symptoms (abdominal pain/discomfort, bloating/distension, bowel movement difficulty) and changes in stool frequency and consistency were recorded daily and assessed each week. A safety assessment was carried out throughout the study. Results: The proportion of responders, defined by an improvement of abdominal pain/discomfort, was significantly higher (p=0.04) in the treated group than the placebo group (63% vs 47%, OR=1.88, 95%, CI: 0.99-3.57) in the last 4 weeks of treatment. A non-significant trend of improvement was observed with Saccharomyces cerevisiae for the other symptoms. Saccharomyces cerevisiae was well tolerated and did not affect stool frequency and consistency. Conclusion: Saccharomyces cerevisiae is well tolerated and reduces abdominal pain/discomfort scores without stool modification. Thus, Saccharomyces cerevisiae may be a new promising candidate for improving abdominal pain in subjects with irritable bowel syndrome. (C) 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据